Regeneron posts 36% revenue jump as Dupixent and Libtayo set records
Regeneron Pharmaceuticals delivered its strongest quarter in several years in the three months to 30 September 2026, with total revenues climbing 36% year-on-year to $5.1 billion. Non-GAAP earnings per share rose 70% to $20.07, a pace the company attributed to record commercial performance across its top three marketed products and the completion of repayment of the Sanofi Development Balance, which had previously reduced collaboration revenue.
Dupixent (dupilumab), the blockbuster IL-4/IL-13 inhibitor commercialised with Sanofi, remained the primary growth engine. Global net sales reached $6.5 billion in the quarter, a 35% increase over the same period in 2025, reflecting continued uptake across its broad label spanning atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and a growing list of additional indications. Regeneron's share of Sanofi collaboration profits rose to $2.6 billion in the quarter from $1.5 billion a year earlier.
Portfolio momentum
EYLEA HD (high-dose aflibercept 8 mg) continued to displace its predecessor product in the US retinal market, with net sales up 62% to $699 million. Legacy EYLEA declined 41% in the same period as patients transitioned. The combined franchise was roughly flat year-on-year, but the shift toward the higher-priced formulation is broadly positive for Regeneron's economics, and the Bayer-partnered ex-US business remains a separate revenue stream. Libtayo (cemiplimab), the PD-1 inhibitor with a growing oncology label, reported global net sales of $550 million, up 51%, with US growth of 81% the standout figure.
On the pipeline, the company received FDA approval for Pasatru (garetosmab) in fibrodysplasia ossificans progressiva, a severe ultra-rare connective-tissue disorder for which no approved therapy previously existed. Eighty-four-week Phase 3 data presented at ASBMR showed sustained suppression of new heterotopic ossification and meaningful reductions in flare frequency. A regulatory application in the EU remains under review.
In October, Regeneron and Sanofi expanded their longstanding antibody alliance to include four next-generation, long-acting antibodies designed to build on Dupixent's immunology platform. Regeneron received a $1.0 billion up-front payment, recognisable in Q4 2026, with up to a further $7.0 billion contingent on development, regulatory, and sales milestones. The companies will equally share costs and future profits on the new programmes globally.
Pipeline and market context
Regeneron carries approximately 50 clinical-stage candidates, a breadth that is unusual among large-cap biotechs and reflects substantial reinvestment of commercial profits into R&D, which reached $1.8 billion on a GAAP basis in the quarter. Near-term catalysts include an FDA decision for cemdisiran in generalised myasthenia gravis, expected in November 2026, and a February 2027 target action date for Ordspono (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma. The EMA's CHMP has also recommended an extended six-week dosing interval for Libtayo, pending European Commission ratification, with a corresponding US supplemental BLA holding a March 2027 target date.
Regeneron's position in the weight-management adjacency is worth watching. The Phase 2 COURAGE trial of trevogrumab, a myostatin antibody intended to preserve lean mass during GLP-1-induced weight loss, produced data presented at EASD in October. The obesity market has attracted intense competition, and Regeneron's muscle-preservation angle differentiates it from the GLP-1 mechanism itself, though clinical utility will ultimately depend on outcomes data not yet available. A CIDEB-targeting RNAi therapy in MASLD/MASH showed a 70% average reduction in liver fat after a single dose in a Phase 1/2 study, with a Phase 3 initiation planned for Q4 2026.
The company repurchased $2.3 billion of its own stock in the nine months to September and declared a quarterly dividend of $0.94 per share. Full-year non-GAAP R&D guidance was lifted to $6.05–$6.15 billion, reflecting pipeline advancement costs.